CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms CONFIRM
- 09 Sep 2017 Trial design of the study presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
- 04 Mar 2017 Status changed from not yet recruiting to recruiting.
- 28 Feb 2017 New trial record